A

It has been about a month since the last earnings report for Agilent Technologies (A). Shares have added about 0.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Agilent Technologies reported second-quarter fiscal 2026 earnings of $1.49 per share, up 13.7% year over year. The figure surpassed the Zacks Consensus Estimate by 6.21%. Quarterly revenues came in at $1.84 billion, which represented 10% reported growth year over year. The figure beat the Zacks Consensus Estimate by 2.12%. Strength in instruments and solid execution also supported a favorable mix, with 66% of fiscal second-quarter revenue coming from recurring streams such as consumables, services and informatics. A’s top-line expansion was broad-based across its three reporting groups. The Life Sciences and Diagnostics Markets Group generated $732 million of revenues, up 12% year over year on a reported basis and 9% on a core basis. Agilent CrossLab delivered $759 million, reflecting 6% reported growth and 2% core growth, while Applied Markets recorded $344 million, increasing 14% reported and 11% core. Segment profitability remained solid, with operating margins of 22.0% in LDG, 32.0% in CrossLab and 23.3% in Applied Markets. For the second quarter of fiscal 2026, the LDG segment’s gross margin expanded 130 basis points (bps) year over year to 54.1%. ACG’s gross margin was flat year over year to 55.5%, while AMG’s gross margin expanded 230 bps year over year to 55.8%.Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general, and administrative (SG&A) expenses on a non-GAAP basis rose to $409 million, marking a 9.4% increase from the prior-year quarter. As a percentage of revenues, R&D expenses fell 20 bps year over year to 6.3%, while SG&A expenses fell 10 bps year over year to 22.3%. Non-GAAP operating margin expanded 130 basis points year over year to 26.4% and improved 180 basis points sequentially. Demand trends varied by end market, but the overall mix remained constructive. Pharma, which represented 36% of quarterly revenue...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Agilent Technologies (A) has been in focus after reporting quarterly results that exceeded analyst expectations on both revenue and earnings. The company raised full-year guidance and paired that update with expansion moves in China and cancer diagnostics. See our latest analysis for Agilent Technologies. Agilent Technologies' latest earnings beat and guidance raise have arrived alongside a 10.53% 1 month share price return and a 13.43% 3 month share price return. The stock's year to date share price return is down 7.89% and the 1 year total shareholder return is 10.85%, suggesting recent momentum has picked up even though longer term performance has been mixed. If you are tracking how lab tools and diagnostics tie into broader AI trends, this is a good moment to look across the market and check out 40 healthcare AI stocks With Agilent Technologies trading at $127.06 against an analyst price target of $160.35 and an estimated intrinsic discount of about 23%, the key question is whether this gap signals a genuine opportunity or if the market is already pricing in future growth. Against the current $127.06 share price, the most followed narrative for Agilent Technologies points to a fair value of $161, anchored on detailed long term forecasts using a 7.94% discount rate. Read the complete narrative. Want to see what is behind that confidence in recurring revenue and margin expansion? The narrative leans heavily on future earnings power, disciplined cost control and a premium profit multiple tied to those projections. Result: Fair Value of $161 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still real pressure points for the Agilent Technologies narrative, especially if tariff related costs stay elevated or if academic and government funding weakens further. Find out about the key risks to this Agilent Technologies narrative. The optimism around Agilent Technologies may feel compelling, but your conclusions should rest on your own review of the facts and risks. To see what is driving that optimism, take a closer look at the 4 key rewards If you stop with Agilent Technologies, you might miss other setups that fit your style. Use the screeners below to keep your watchlist sharp and in...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at research tools & consumables stocks, starting with Agilent (NYSE:A). The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.3% while next quarter’s revenue guidance was 2% above. Thankfully, share prices of the companies have been resilient as they are up 8.5% on average since the latest earnings results. Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets. Agilent reported revenues of $1.84 billion, up 10% year on year. This print exceeded analysts’ expectations by 1.9%. Overall, it was a strong quarter for the company with an impressive beat of analysts’ organic revenue estimates and a narrow beat of analysts’ full-year EPS guidance estimates. Agilent scored the highest full-year guidance raise but had the weakest guidance update of the whole group. Unsurprisingly,...

Agilent’s second quarter saw a positive market reaction, underpinned by broad-based revenue growth and notable operating margin expansion. Management credited the quarter’s outperformance to strong demand across key end markets, robust instrument sales, and the benefits of its Ignite operating system. CEO Padraig McDonnell highlighted that “replacement site momentum, innovation-led share gains, and improving operational execution” were central to Agilent’s results, while the company’s strategic pricing initiatives and ongoing productivity efforts further supported profitability. Is now the time to buy A? Find out in our full research report (it’s free). Revenue: $1.84 billion vs analyst estimates of $1.80 billion (10% year-on-year growth, 1.9% beat) Adjusted EPS: $1.49 vs analyst estimates of $1.41 (5.8% beat) The company slightly lifted its revenue guidance for the full year to $7.44 billion at the midpoint from $7.4 billion Management raised its full-year Adjusted EPS guidance to $6.05 at the midpoint, a 1.3% increase Operating Margin: 21.7%, up from 18% in the same quarter last year Organic Revenue rose 6.3% year on year (beat) Market Capitalization: $38.14 billion While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Vijay Kumar (Evercore) asked about the sustainability of CAM growth and instrument strength; CEO Padraig McDonnell credited CAPEX momentum in semiconductors and downstream materials, noting, “investment in the semiconductor space continues to be a real sweet spot for us.” Patrick Donnelly (Citi) inquired about visibility and contract coverage in advanced therapeutics; President Simon May responded that “phasing of production schedules point towards very strong year-over-year growth in the third quarter,” with good line of sight into demand for 2027. Tycho Peterson (Jefferies) questioned the sustainability of double-digit spectroscopy growth and pricing power; McDonnell cited pent-up demand and new product launches as drivers, describing the semiconductor market as contributing about 30% of advanced materials sales. Catherine Schulte (Baird) asked about the food segment’s guidance reduction; McDonnell expla...

Agilent Technologies, Inc. A used its second-quarter fiscal 2026 earnings call to make a broader point than a simple beat-and-raise. Management framed the quarter as evidence that the company’s Ignite operating system is now producing more durable benefits across pricing, execution, and margins. That mattered because Agilent paired better-than-expected quarterly results with a higher full-year outlook while arguing that replacement cycles, innovation, and operational discipline can keep supporting growth even as comparisons get tougher. CEO Padraig McDonnell said the company delivered broad-based strength across major end markets, but he spent as much time on operating discipline as on demand. He said Ignite is becoming structurally embedded in the business and is helping Agilent convert healthy conditions into stronger financial performance. That message was backed by the quarter’s numbers. Revenue rose 10% to $1.84 billion, or 6.3% on a core basis, while adjusted EPS reached $1.49. EPS topped the Zacks Consensus Estimate of $1.40 by 6.21%, and revenues beat the $1.8 billion estimate by 2.12%. Management’s tone suggested the bigger takeaway was the quality of growth. McDonnell said Agilent hit or exceeded its long-term plan on revenue growth, margin expansion, and EPS growth in the quarter. McDonnell highlighted pharma, chemicals and advanced materials, diagnostics, and forensics as the main sources of strength. Pharma grew 6%, chemicals and advanced materials rose 8%, and diagnostics and clinical increased 11%, while forensics posted growth of more than 50%. He also pointed to continued instrument momentum. Agilent reported high single-digit instrument growth, including low double-digit growth in LC, LC/MS, and GC, supported by replacement demand and market share gains. The segment view in the press release reinforced that breadth. Life Sciences and Diagnostics Markets revenue rose 12% on a reported basis, CrossLab increased 6%, and Applied Markets climbed 14%. Management tied that demand backdrop to a busy product cycle. McDonnell previewed launches at ASMS, including the new 9500 triple quadrupole ICP-MS platform and upgraded flagship gas chromatography systems, while also highlighting traction in columns and OpenLab software. Pricing was another major theme. McDonnell said strategic pricing contributed about 200 basis points in the quarter, putting Agil...

June S&P 500 E-Mini futures (ESM26) are trending up +0.18% this morning as investors became more confident that the U.S. and Iran are nearing a deal. The U.S. and Iran have reportedly reached a tentative deal to extend the ceasefire by 60 days, which would include the reciprocal reopening of the Strait of Hormuz during the first 30 days. It would mark the first phase of a multistage framework, which the U.S. hopes will result in Iran scaling back its nuclear program for decades. “We perhaps have the makings of a deal here,” Treasury Secretary Scott Bessent said on Thursday. A deal is reportedly awaiting approval from U.S. President Donald Trump. The price of WTI crude fell over -1% on Friday. ARM Stock Is Valued for Eternity, But Silicon Has an Expiration Date Ford Stock Is Moving Like Tesla Now. Its Results Can’t Justify the Premium. S&P 500 and Nasdaq 100 Post Record Highs on US-Iran Truce Reports Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! “If a deal is agreed upon, we should see another leg higher in risky assets and lower in rates. Positioning suggests that the rates market should see a greater reaction than equities,” said Mohit Kumar at Jefferies. Sentiment was also supported by some positive corporate news. Dell Technologies (DELL) popped over +37% in pre-market trading after the hardware maker posted upbeat Q1 results and raised its full-year revenue guidance amid surging demand for servers that power AI workloads. Also, Okta (OKTA) climbed more than +7% in pre-market trading after the company reported stronger-than-expected Q1 results and boosted its annual guidance. In yesterday’s trading session, Wall Street’s major indices closed higher, with the S&P 500 and Nasdaq 100 notching new record highs. Chip stocks climbed, with Arm Holdings (ARM) jumping more than +10% and Advanced Micro Devices (AMD) rising over +4%. Also, Snowflake (SNOW) popped over +36% after the data warehousing company reported strong Q1 results, raised its full-year product revenue guidance, and expanded its collaboration with Amazon Web Services. In addition, Agilent Technologies (A) surged more than +16% and was among the top percentage gainers on the S&P 500 after the company posted upbeat FQ2 results and raised its full-year guidance. On th...

Agilent Technologies stock surges as Wall Street approves of the company’s second-quarter earnings and guidance update.

Agilent Technologies A reported second-quarter fiscal 2026 earnings of $1.49 per share, up 13.7% year over year. The figure surpassed the Zacks Consensus Estimate by 6.21%. Quarterly revenues came in at $1.84 billion, which represented 10% reported growth year over year. The figure beat the Zacks Consensus Estimate by 2.12%. Strength in instruments and solid execution also supported a favorable mix, with 66% of fiscal second-quarter revenue coming from recurring streams such as consumables, services and informatics. A’s top-line expansion was broad-based across its three reporting groups. The Life Sciences and Diagnostics Markets Group generated $732 million of revenues, up 12% year over year on a reported basis and 9% on a core basis. Agilent CrossLab delivered $759 million, reflecting 6% reported growth and 2% core growth, while Applied Markets recorded $344 million, increasing 14% reported and 11% core. Segment profitability remained solid, with operating margins of 22.0% in LDG, 32.0% in CrossLab and 23.3% in Applied Markets. Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote For the second quarter of fiscal 2026, the LDG segment’s gross margin expanded 130 basis points (bps) year over year to 54.1%. ACG’s gross margin was flat year over year to 55.5%, while AMG’s gross margin expanded 230 bps year over year to 55.8%. Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general, and administrative (SG&A) expenses on a non-GAAP basis rose to $409 million, marking a 9.4% increase from the prior-year quarter. As a percentage of revenues, R&D expenses fell 20 bps year over year to 6.3%, while SG&A expenses fell 10 bps year over year to 22.3%. Non-GAAP operating margin expanded 130 basis points year over year to 26.4% and improved 180 basis points sequentially. Demand trends varied by end market, but the overall mix remained constructive. Pharma, which represented 36% of quarterly revenues, delivered 6% core growth and marked a fifth straight quarter of mid-single to low-double-digit growth, including low-double-digit growth in biotech. Diagnostics and Clinical (16% of revenue) rose 11% on core growth, supported by expansion in Cancer Diagnostics offerings and traction for the Omnis family. Chemicals and Advanced Materials (23% of revenue) inc...

Investing.com -- Bank of America upgraded Agilent Technologies to “Buy” from “Neutral,” citing strong execution, market share gains, and resilience across key end markets despite broader concerns in the life sciences tools sector. The brokerage set a new price objective of $145, slightly below its prior $150 target, while maintaining confidence in the company’s long-term growth outlook. The upgrade follows Agilent’s fiscal second-quarter results, where the company exceeded expectations across several metrics. Core revenue growth came in at 6.3%, above the high end of guidance, while operating margins and adjusted earnings per share also topped forecasts. Analysts highlighted continued strength in liquid chromatography (LC), gas chromatography (GC), and LC/MS replacement cycles, which they said remain in the “early innings” of growth. BofA analysts noted that Agilent’s instruments business delivered high single-digit growth during the quarter, supported by competitive wins, innovation-led displacement, and improving market share trends. Management also pointed to demand expanding beyond simple replacement activity, as new product platforms gain traction among existing customers. The company’s Chemical and Advanced Materials (CAM) segment also performed better than expected, posting 8% core growth driven by strength in semiconductor and chemicals markets. Analysts said GC replacement activity tied to aging equipment fleets helped fuel momentum, particularly in the Americas and Asia outside China, while spectroscopy demand remained robust across semiconductor and advanced materials workflows. Agilent modestly raised its full-year guidance after the quarterly beat, with management expressing a more constructive outlook on CAM, forensics, and diagnostics markets, although conditions in food testing remain softer. BofA expects second-half revenue and margin progression to remain achievable despite tougher year-over-year comparisons. The brokerage also revised its earnings estimates upward, forecasting adjusted EPS of $6.05 for 2026 and $6.65 for 2027, compared with prior estimates of $5.97 and $6.57, respectively. Related articles Agilent stock gets ’buy’ upgrade from BofA after impressive quarterly beat These 2 stocks are best positioned to benefit from higher uranium prices: analyst This sector is 'poised for a big, beautiful year': Truist

Agilent Technologies Inc (NYSE:A) shares climbed 19% on Thursday after the company posted stronger-than-expected fiscal second quarter results and received an upgrade from Bank of America, which pointed to improving demand trends and continued market share gains in key instrument categories. Bank of America upgraded Agilent to ‘Buy’ from ‘Neutral,’ saying the company is showing “strong execution” despite uneven conditions across several end markets. The analysts highlighted durable demand for gas chromatography (GC) and liquid chromatography (LC) instruments, supported by replacement cycles, new product platforms, and competitive wins. Agilent reported 6.3% core revenue growth for the quarter, above the high end of its guidance range. Operating margin also exceeded expectations by 80 basis points, while adjusted earnings per share beat consensus estimates by $0.08. According to the Bank of America analysts, the instruments segment delivered high-single-digit growth, with continued low double-digit expansion in LC/LC-MS and GC businesses. Management said Agilent is seeing some of the strongest market share trends in recent years, driven by innovation-led displacement of competitors and growing adoption of new platforms across existing customer accounts. The analysts also noted that demand appears to be increasingly supported by more than just replacement activity alone, suggesting a broader improvement in customer spending patterns. Agilent’s chemicals and advanced materials (CAM) segment was another area of strength, posting 8% core growth. Bank of America said results and management commentary in the segment were “better than feared,” particularly given broader concerns about slowing chemicals demand across the analytical tools industry. Strength was seen in both semiconductor and chemicals markets, with spectroscopy remaining a standout in semiconductor, high-purity chemicals, and advanced materials workflows. The company also benefited from GC replacement activity tied to aging instrument fleets, particularly in the Americas and Asia excluding China, though Europe also showed strength. Agilent raised its full-year guidance roughly in line with the scale of the quarterly beat. While the analysts noted that comparisons become more challenging in the second half of the year, Bank of America said the company’s outlook for revenue and margin progression appear...

SANTA CLARA, Calif. (AP) — SANTA CLARA, Calif. (AP) — Agilent Technologies Inc. (A) on Wednesday reported fiscal second-quarter earnings of $339 million. The Santa Clara, California-based company said it had net income of $1.20 per share. Earnings, adjusted for one-time gains and costs, were $1.49 per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.40 per share. The scientific instrument maker posted revenue of $1.84 billion in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $1.8 billion. For the current quarter ending in July, Agilent expects its per-share earnings to range from $1.48 to $1.50. The company said it expects revenue in the range of $1.83 billion to $1.85 billion for the fiscal third quarter. Agilent expects full-year earnings in the range of $6 to $6.10 per share, with revenue ranging from $7.39 billion to $7.49 billion. Agilent shares have dropped 15% since the beginning of the year, while the S&P's 500 index has risen roughly 10%. In the final minutes of trading on Wednesday, shares hit $115.82, a rise of 4% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on A at https://www.zacks.com/ap/A

Interested in Agilent Technologies, Inc.? Here are five stocks we like better. Agilent raised its fiscal 2026 outlook after a strong second quarter, with revenue of $1.83 billion, non-GAAP EPS of $1.49, and operating margin expansion to 26.4% all beating guidance. The company now expects full-year core revenue growth of 4.5% to 6% and non-GAAP EPS of $6.00 to $6.10. Broad-based demand helped results across key end markets, led by pharma, chemicals and advanced materials, diagnostics and clinical, and environmental and forensics. Instrument replacement momentum, pricing actions, and the Ignite operating system also contributed to growth and margin gains. Management highlighted continued strength in instruments and future launches, including low-double-digit growth in LC, LC-MS and GC, plus new product introductions in mass spectrometry, chromatography and software. Agilent also said it fully offset tariff impacts and remains confident in its China and diagnostics outlook. Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? Agilent Technologies (NYSE:A) raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system. CEO Padraig McDonnell said Agilent delivered “an excellent second quarter” with revenue of $1.83 billion, up 6.3% on a core basis and above the high end of the company’s guidance. Non-GAAP operating margin expanded to 26.4%, up 130 basis points from a year earlier, while non-GAAP earnings per share rose 14% to $1.49, exceeding the top end of guidance by $0.07. → Voya Financial Grows Earnings Across All 3 Business Segments Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak “We delivered at or above our long-term plan on all metrics, revenue growth, margin expansion and EPS growth,” McDonnell said. He said the quarter showed that benefits from the company’s Ignite operating system are becoming “structurally embedded” in the business. McDonnell said Agilent’s performance was supported by strength across several of its largest markets. Pharma revenue grew 6% in the quarter, including another period of low-double-digit growth in biotech, led by large-cap customers. Small molecule pharma grew in the low single di...